International Scientific Advisory Committee

The International Scientific Advisory Committee is an external group of individuals with expertise in Kids Brain Health Network’s areas of focus. The committee informs the CEO and Interim Chief Scientific Officer, as well as the Network’s Research Management Committee (RMC) and Board of Directors on research planning and strategy in domains such as optimizing the selection of projects supported by KBHN, and maximizing the impact of research results.

Devlin’s research has two major foci, the development of statistical methods for the analysis of genetic data and the implementation of those methods to discover the genetic basis of disease, especially autism, schizophrenia, and neurodegenerative disorders. His work has been recognized by admission as a fellow to the American Association for the Advancement of Science. He chaired of the Access Committee for the Center for Inherited Disease Research (CIDR), which is a U.S. government-funded genotyping center that performs massive genotyping and sequencing. The CIDR Access Committee or CAC is charged with judging the value of proposals for access to CIDR for genomewide association studies, among other kinds of genetic studies.
Mark hoffman, vice president, LifeSciences Solutions, is responsible for Cerner’s LifeSciences development initiatives, including genomics, clinical trials, Galt, and the Cerner Discovere™ and HIV Insight® solutions. In his current role, Hoffman is charged with reducing the barriers between patient care and clinical research and enhancing Cerner’s role in the pharmaceutical industry. Hoffman serves as a member of the Evaluating Genomics Applications in Practice and Prevention (EGAPP) Stakeholder group, for which he is co-chair of the informatics sub-committee. He also is a member of the RAND Corp. initiative on genetic test reporting. He recently served on the Secretary of HHS Advisory Committee on Genomics Health and Society (SACGHS) task force on Genetic Testing Oversight and contributed to the informatics chapter of the task force report. Hoffman earned a bachelor’s degree in molecular biology from William Jewell College in Liberty, Mo., and a Ph.D. in bacteriology from the University of Wisconsin-Madison. He also completed a bioethics study from Oxford University while at William Jewell.
Dr. Johnston holds the Blum/Moser Chair for Pediatric Neurology at the Hugo Moser Research Institute and Kennedy Krieger Institute in Baltimore and he is a Professor of Neurology, Pediatrics and Physical Medicine and Rehabilitation at Johns Hopkins University School of Medicine. He is also the Chief Medical Officer and Executive Vice President of Kennedy Krieger. His laboratory and clinical research team work on the discovery of new therapies for developmental brain disorders including neonatal hypoxic-ischemic encephalopathy, perinatal stroke, white matter disorders of prematurity, Rett syndrome and tuberous sclerosis. They are especially interested in harnessing endogenous plasticity mechanisms to improve outcome.
Edward P. Riley (Ph.D., 1974, Tulane University) is a Distinguished Professor of Psychology and Director of the Center for Behavioral Teratology at San Diego State University. He has authored over 250 scientific papers and reviews and served as Chair of the U.S. National Task Force on FAS/FAE from 2000-2004 at the request of the US Secretary of Health. He currently serves on the Expert Panel for the SAMHSA FASD Center for Excellence. He is a Past-President of the Research Society on Alcohol (RSA) and is currently a Reviewing Editor for Alcoholism: Clinical and Experimental Research. He is currently a member of the National Institute on Alcohol Abuse and Alcoholism Council. He has received numerous awards for his scholarship including the RSA Distinguished Researcher Award and the NoFAS Research Recognition Award.